IBRX
ImmunityBioANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Q1 preliminary revenue growth, expanding ANKTIVA geographic reach, and a fully enrolled QUILT-2.005 study support a real commercial-plus-regulatory path if the upcoming 10-Q validates the preliminary figures and 2026 regulatory milestones stay on track [#8-K-2026-04-09].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.1.
What can break
Formal Q1 2026 results could disappoint versus the April 9 preliminary figures.
Momentum
91
Value
41
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $11.00 · Bear $4.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $14.00
Why
Momentum91 · Δ7d +0.1
Value41 · Δ7d +0.1
Sentiment54 · Δ7d +3.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
91
34% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+4.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
54
33% active weight
Current posture
7d trendImproving
Δ7d
+3.2
Δ21d
+19.2
Why this grade
Composite grade A. Momentum 90.6 / Value 41.1 / Sentiment 54.4
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$7.58B
Beta
-0.02
Shares Out
984.97M
P/E (TTM) · Derived
-20.2
P/S (TTM)
24.82
P/FCF (TTM) · Derived
-20.28
Rev YoY
+425.1%
EPS YoY
+42.3%
Gross Margin
+90.4%
Op Margin
-315.8%
Net Debt
$597.72M
Current Ratio
5.77
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology